Evidence map›Paper›PMID 39865824›Full record

ArticleCurrent pharmaceutical design2025

Crosstalk: Biochemical Signatures and Clinical Implications in Rare Hereditary Hemolytic Anemias (Hereditary Spherocytosis).

Faris Abdullah Al Toub, Amer Hamzah Obaied Asseri, Mirza Rafi Baig, Naif Abdullah R Almalki, Firoz Anwar

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Faris Abdullah Al ToubDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Amer Hamzah Obaied AsseriDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Mirza Rafi BaigDepartment of Clinical Pharmacy & Pharmacotherapeutics, Dubai Pharmacy College for Girls, Dubai Medical University, Dubai, United Arab Emirates.
Naif Abdullah R AlmalkiDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.
Firoz AnwarDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia.ORCID 0000-0003-3553-3512

Funding

Deanship of Scientific Research for King Abdulaziz University, Jeddah GPIP: 228-130-2024
6 · The paper itself

Abstract

backgroundClinical Hereditary Hemolytic Anemia (HAA) particularly Hereditary Spherocytosis (HS) encompasses diverse genetic disorders causing premature red blood cell destruction and intrinsic RBC defects. There's a pressing need for standardized diagnostic protocols tailored to the Asian population, particularly in Saudi Arabia, underscoring the significance of thorough blood biochemistry analysis. MATERIALS AND

methodsA case-control prospective study was conducted at King Abdulaziz University, samples were obtained from King Fahad Hospital, Jeddah, Saudi Arabia, serving a significant population, and blood samples from 27 patients meeting ethical criteria for HHA and HS. Inclusion criteria included diagnosed patients of any age and sex, while exclusion criteria encompass chronic infections, metabolic diseases, pregnancy, and lactation. Blood profiling was conducted following strict protocols, aiming to glean insights into patients' management and therapeutic strategies. Despite an intended larger sample size, limitations in availability led to the inclusion of 27 patient analyses.

resultsAmong 27 participants, males comprised 59.3%, females 40.7%. Anemia types indicated 22.2% Type 1 (HHA) and 77.8% Type 3 (HS). Age groups (<30, 31-59, ≥60 years) highlighted HS prevalence, notably in older individuals. Blood pressure analysis revealed age-related increases, especially in those over 60 with systolic BP (147.33 ± 9.86 mm/Hg) (p≤0.02) and diastolic BP (85.67 ± 9.01 mm/Hg) (p≤0.03) emphasizing agespecific monitoring. Temperature variations were noted across ages, significant in patients over 60 (35.93 ± 1.100C) (p≤0.09), indicating potential clinical relevance. Iron levels showed no age-related differences, while Blood Urea Nitrogen (BUN) levels rose with age, particularly in those over 60 (35.83 ± 16.67 mm/dL) (p≤0.04), suggesting age-related influence. Alkaline Phosphatase levels increased with age, especially in patients aged 31 to 59 (205.80 ± 123.17IU/L)(p≤0.001), warranting further investigation. Similarly, Aspartate Transferase levels rose with age, especially in patients aged 31 to 59 (134.69 ± 284.58 U/L) (p≤0.01), underlining age-specific considerations. Notable differences in BUN (15.03 mm/dL and 29.06 mm/dL) and Aspartate Transferase (33.01 U/L and 115.66 U/L) levels were observed among different anemia types with no major significant alteration in LDH.

conclusionThe results suggest unique biochemical signatures with potential renal and hepatic implications, underscoring the importance of biochemical assessment in managing hereditary hemolytic anemias, particularly HS.

Indexed as

Spherocytosis, HereditaryAdolescentAdultAgedCase-Control StudiesFemaleHumansMaleMiddle AgedProspective StudiesSaudi ArabiaYoung Adultenzymopathieshemoglobinhemoglobinopathies.Hereditary hemolytic anemiainherited genetic disorderred blood cells

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.